🧬 Illumina: War Over The Holy Grail?

Microsoft wins US Army contract. Amazon has a tax problem.


Hey Global Investor, here’s what you need to know before the US markets open.

Market Snapshot 📈

S&P 500 (Yesterday’s Close) 3,972.89 +14.34 (0.36%)

NASDAQ (Yesterday’s Close) 13,246.87 +201.48 (1.54%)

FTSE 100 (5 PM IST) 6,743.16 +29.53 (0.44%)

NIFTY 50 (Friday’s Close) 14,867.35 +176.65 (1.20%)

USDINR (5 PM IST) 73.11 (1 Year -6.44%)

 

 


🔥 Top Movers

MVIS +50.69%
ABCL +27.29%
CONN +23.28%

UI -14.53%
LABD -12.87%
HGEN -11.88%

 


🧬 Illumina: War Over The Holy Grail?

Illumina Inc. (ILMN) has been denied its $7.1B acquisition of Grail Inc by the Federal Trade Commission (FTC). Illumina is set to contest the decision. (Tweet This)

Background
Founded in 1998, Illumina Inc. (ILMN) is a DNA sequencing machine maker. The company designs, manufactures, and markets integrated systems for analyzing genetic variations. Illumina serves customers in the research, clinical, and applied markets.  The company went public in 2000 and currently has a market valuation of $56.03B.

In 2020, Illumina announced that it would acquire Grail for $7.1B, after Grail’s breakthrough multi-cancer detection blood test. Illumina stated that the merger would enable Grail to make the test available to the population at large in a faster and cheaper manner that will help save lives.

Grail was originally founded by Illumina in 2016 to screen for multiple early-stage cancers. A total of $100M was raised as part of the Series A round with the investor roster including notable names such as Bill Gates and Jeff Bezos. Eventually, Grail spun-off to chart its own course; Illumina today holds a 12% stake in the company.

What Happened?: The FTC shot down Illumina’s acquisition, citing concerns of anti-competitive and monopolistic practices. Illumina’s hardware is used by pretty much all of Grail’s competitors in the US. The FTC reasons that Illumina can charge higher prices to these competitors when selling them the next-generation sequencing instruments and consumables.

This isn’t the first time Illumina has faced the music from the FTC. In 2019, the FTC and its U.K. counterpart challenged Illumina’s planned $1.2 billion purchase of Pacific Biosciences. The deal was eventually abandoned.

Illumina, for its part, has vowed to vigorously defend its plans and will continue to pursue Grail. Illumina contends the merger will not unfairly impact competition and it offers contractual guarantees of “equal and fair access” to its customers.

While Illumina’s distribution experience and Grail’s innovation would greatly benefit both companies, the adoption by customers of Grail’s liquid biopsy cancer screening tools remains highly uncertain. It remains to be seen whether Illumina has the staying power this time around in the face of a skeptical FTC that may be unwilling to yield ground. The battle lines have now been drawn. Investors are optimistic Illumina has a case to be made that its acquisition plans should be allowed to go through.

Market reaction: ILMN ended the day at $384.06, up 4.09%. The stock is up 2.04% in pre-market trading.

Company Snapshot 📈

ILMN $384.06 +15.10 (4.09%)

Analyst Ratings
(19 Analysts) BUY 32%   HOLD 42%   SELL 26%


Newsworthy 📰

Taxes: Biden singles out Amazon for not paying federal taxes (AMZN +1.27%)

Army Tech: Microsoft wins $21.9 billion contract with U.S. Army to supply AR headsets (MSFT +1.69%)

Partners: German process mining startup Celonis teams up with IBM and Red Hat (IBM  -1.08%)

 


Later Today 🕒

  • 6:00 PM IST: Initial jobless claims
  • 7:30 PM IST: ISM manufacturing index

Fun Fact of The Day 🌞

Banging your head against a wall for one hour burns 150 calories


Disclaimer: The content of this article has been created and published by Winvesta India Technologies Pvt. Ltd., in order to ease the reader’s understanding of the subject matter. The information and/or content (collectively “Information”) provided herein is general information sourced through various news reports and does not constitute a research report or a research analysis. The Information is not intended to offer advice, target or solicit any particular customer or group of customers to buy or sell securities. 

Winvesta does not render any research or advisory services and provides a more detailed description of its services on its website and mobile application along with the terms and conditions published therein from time to time. While reasonable care has been exercised to ensure that the Information is adequate and reliable, no representation is made by Winvesta as to its accuracy or completeness and Winvesta, its affiliates, subsidiaries and employees accept no liability of whatsoever nature for any direct or consequential loss, including without limitation any loss of profits, arising from reliance on this Information. Neither Winvesta nor any of its affiliates are acting as an investment adviser, research analyst or in any other fiduciary capacity. Accordingly, reader’s are expected to undertake their own due diligence in consultation with their own advisors and are advised not to solely rely on the Information. Any such reliance shall be at the reader’s own risk. 

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing.


Start Building Your Global Portfolio Today

Download Winvesta App now to Get Started